Literature DB >> 24021671

Essential role of PR-domain protein MDS1-EVI1 in MLL-AF9 leukemia.

Yi Zhang1, Kristina Owens, Layla Hatem, Carolyn H Glass, Kannan Karuppaiah, Fernando Camargo, Archibald S Perkins.   

Abstract

A subgroup of leukemogenic mixed-lineage leukemia (MLL) fusion proteins (MFPs) including MLL-AF9 activates the Mecom locus and exhibits extremely poor clinical prognosis. Mecom encodes EVI1 and MDS1-EVI1 (ME) proteins via alternative transcription start sites; these differ by the presence of a PRDI-BF1-RIZ1 (PR) domain with histone methyltransferase activity in the ME isoform. Using an ME-deficient mouse, we show that ME is required for MLL-AF9-induced transformation both in vitro and in vivo. And, although Nup98-HOXA9, MEIS1-HOXA9, and E2A-Hlf could transform ME-deficient cells, both MLL-AF9 and MLL-ENL were ineffective, indicating that the ME requirement is specific to MLL fusion leukemia. Further, we show that the PR domain is essential for MFP-induced transformation. These studies clearly indicate an essential role of PR-domain protein ME in MFP leukemia, suggesting that ME may be a novel target for therapeutic intervention for this group of leukemias.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24021671      PMCID： PMC3799001          DOI： 10.1182/blood-2012-08-453662

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  24 in total

1.  Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL.

Authors:  C Lavau; S J Szilvassy; R Slany; M L Cleary
Journal:  EMBO J       Date:  1997-07-16       Impact factor: 11.598

2.  Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein.

Authors:  Nathan C Shaner; Robert E Campbell; Paul A Steinbach; Ben N G Giepmans; Amy E Palmer; Roger Y Tsien
Journal:  Nat Biotechnol       Date:  2004-11-21       Impact factor: 54.908

3.  The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression.

Authors:  Ya-Xiong Chen; Jizhou Yan; Karen Keeshan; Anthony T Tubbs; Haoren Wang; Albert Silva; Eric J Brown; Jay L Hess; Warren S Pear; Xianxin Hua
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-13       Impact factor: 11.205

4.  Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.

Authors:  A V Krivtsov; M E Figueroa; A U Sinha; M C Stubbs; Z Feng; P J M Valk; R Delwel; K Döhner; L Bullinger; A L Kung; A M Melnick; S A Armstrong
Journal:  Leukemia       Date:  2012-12-13       Impact factor: 11.528

5.  Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia.

Authors:  Tim C P Somervaille; Michael L Cleary
Journal:  Cancer Cell       Date:  2006-10       Impact factor: 31.743

6.  The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis.

Authors:  C L Dobson; A J Warren; R Pannell; A Forster; I Lavenir; J Corral; A J Smith; T H Rabbitts
Journal:  EMBO J       Date:  1999-07-01       Impact factor: 11.598

7.  Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group.

Authors:  G H Reaman; R Sposto; M G Sensel; B J Lange; J H Feusner; N A Heerema; M Leonard; E J Holmes; H N Sather; T W Pendergrass; H S Johnstone; R T O'Brien; P G Steinherz; P M Zeltzer; P S Gaynon; M E Trigg; F M Uckun
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

8.  Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium.

Authors:  L B Silverman; T W McLean; R D Gelber; M J Donnelly; D G Gilliland; N J Tarbell; S E Sallan
Journal:  Cancer       Date:  1997-12-15       Impact factor: 6.860

9.  Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse.

Authors:  Shigemi Hayashi; Andrew P McMahon
Journal:  Dev Biol       Date:  2002-04-15       Impact factor: 3.582

10.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Authors:  Andrei V Krivtsov; David Twomey; Zhaohui Feng; Matthew C Stubbs; Yingzi Wang; Joerg Faber; Jason E Levine; Jing Wang; William C Hahn; D Gary Gilliland; Todd R Golub; Scott A Armstrong
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962
View more
  8 in total

Review 1.  Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

Authors:  Bin E Li; Patricia Ernst
Journal:  Exp Hematol       Date:  2014-09-28       Impact factor: 3.084

Review 2.  The molecular mechanics of mixed lineage leukemia.

Authors:  R K Slany
Journal:  Oncogene       Date:  2016-02-29       Impact factor: 9.867

3.  Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin.

Authors:  Na Man; Xiao-Jian Sun; Yurong Tan; Marta García-Cao; Fan Liu; Guoyan Cheng; Megan Hatlen; Haiming Xu; Ronit Shah; Nolan Chastain; Na Liu; Gang Huang; Yuan Zhou; Mengyao Sheng; Junhong Song; Feng-Chun Yang; Robert Benezra; Stephen D Nimer; Lan Wang
Journal:  Blood       Date:  2016-03-04       Impact factor: 22.113

4.  EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase.

Authors:  Yusuke Saito; Daisuke Sawa; Mariko Kinoshita; Ai Yamada; Sachiyo Kamimura; Akira Suekane; Honami Ogoh; Hidemasa Matsuo; Souichi Adachi; Takashi Taga; Daisuke Tomizawa; Motomi Osato; Tomoyoshi Soga; Kazuhiro Morishita; Hiroshi Moritake
Journal:  Haematologica       Date:  2019-10-24       Impact factor: 9.941

5.  EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription.

Authors:  Edward Ayoub; Michael P Wilson; Kathleen E McGrath; Allison J Li; Benjamin J Frisch; James Palis; Laura M Calvi; Yi Zhang; Archibald S Perkins
Journal:  Nat Commun       Date:  2018-10-12       Impact factor: 14.919

6.  Overexpression of PRDM5 promotes acute myeloid leukemia cell proliferation and migration by activating the JNK pathway.

Authors:  Pan Zhou; Xing Chen; Mengke Li; Xiaolu Sun; Jiaqi Tan; Xiaomin Wang; Yajing Chu; Yicheng Zhang; Tao Cheng; Jianfeng Zhou; Gaoxiang Wang; Weiping Yuan
Journal:  Cancer Med       Date:  2019-05-23       Impact factor: 4.452

7.  MECOM/PRDM3 and PRDM16 Serve as Prognostic-Related Biomarkers and Are Correlated With Immune Cell Infiltration in Lung Adenocarcinoma.

Authors:  Meng Li; Hui Ren; Yanpeng Zhang; Na Liu; Meng Fan; Ke Wang; Tian Yang; Mingwei Chen; Puyu Shi
Journal:  Front Oncol       Date:  2022-01-31       Impact factor: 6.244

8.  All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia.

Authors:  Chi Huu Nguyen; Katharina Bauer; Hubert Hackl; Angela Schlerka; Elisabeth Koller; Anastasiya Hladik; Dagmar Stoiber; Johannes Zuber; Philipp B Staber; Andrea Hoelbl-Kovacic; Louise E Purton; Florian Grebien; Rotraud Wieser
Journal:  Cell Death Dis       Date:  2019-12-10       Impact factor: 8.469
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.